Martin Moik

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger et al. · Annals of Oncology · 2014 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer

Hanno Riess, A. Helm, Marco Niedergethmann et al. · Journal of Clinical Oncology · 2005 · 102 citations

Medicine, Oncology, Pharmacotherapy +14

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)

Markus Hutterer, Martha Nowosielski, Johannes Haybaeck et al. · Neuro-Oncology · 2013 · 75 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study

Richard Greil, Martin Moik, Roland Reitsamer et al. · European Journal of Surgical Oncology · 2009 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

Michael Gnant, G. Steger, Richard Greil et al. · Cancer Research · 2018 · 37 citations

Medicine, Oncology, Pharmacotherapy +17